Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2003-09-08
2010-02-02
Li, Q. Janice (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100
Reexamination Certificate
active
07655772
ABSTRACT:
The present invention pertains to a method for treatment of allergic diseases by administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP, to a patient in need thereof. In another aspect, the present invention concerns an expression vector comprising a nucleic acid sequence encoding NHP. In another aspect, the present invention concerns a host cell genetically modified with a nucleic acid sequence encoding NHP. In another aspect, the present invention concerns a pharmaceutical composition comprising NHP or a nucleic acid sequence encoding NHP and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to novel fragments of atrial natriuretic peptide (ANP) exhibiting bronchodilatory and anti-inflammatory activity, and isolated nucleic acid sequences encoding the fragments.
REFERENCES:
patent: 5691310 (1997-11-01), Vesely
patent: 5840341 (1998-11-01), Watts et al.
patent: 6013630 (2000-01-01), Shimkets
patent: 6528245 (2003-03-01), Sanchez-Ramos et al.
patent: 6943147 (2005-09-01), Vesely
patent: 2001/0027181 (2001-10-01), Kitakaze et al.
patent: 2002/0146821 (2002-10-01), Sanchez-Ramos et al.
patent: 2003/0069186 (2003-04-01), Burnett et al.
patent: 2003/0073628 (2003-04-01), Shailubhai et al.
patent: 2003/0147943 (2003-08-01), Luo et al.
patent: 2003/0204063 (2003-10-01), Gravel et al.
patent: 2004/0002458 (2004-01-01), Seilhamer et al.
patent: 2004/0067889 (2004-04-01), Belenky et al.
patent: 2004/0138134 (2004-07-01), Golembo et al.
patent: 2004/0146549 (2004-07-01), Ben-Sasson et al.
patent: 2004/0171550 (2004-09-01), Backstrom et al.
patent: 2004/0203081 (2004-10-01), James et al.
patent: 2004/0213782 (2004-10-01), Wax et al.
patent: 2004/0224903 (2004-11-01), Berry et al.
patent: 2004/0266673 (2004-12-01), Bakis et al.
patent: 2005/0014287 (2005-01-01), Friese et al.
patent: 2005/0014289 (2005-01-01), Parsons et al.
patent: 2005/0209139 (2005-09-01), Vesely
patent: 2005/0272650 (2005-12-01), Mohapatra
patent: 2006/0014689 (2006-01-01), Vesely
patent: 2006/0110359 (2006-05-01), Sanchez-Ramos et al.
patent: 2007/0265204 (2007-11-01), Mohapatra
patent: 2008/0039394 (2008-02-01), Vesely
patent: 2008/0070858 (2008-03-01), Mohapatra
patent: 2008/0214437 (2008-09-01), Mohapatra et al.
patent: 2009/0062206 (2009-03-01), Vesely
patent: 2009/0170196 (2009-07-01), Vesely
patent: 2009/0176706 (2009-07-01), Mohapatra
patent: WO 00/71576 (2000-11-01), None
patent: WO 2005/094420 (2005-10-01), None
Lin et al, Hum Gene Ther 1998;9:1429-38.
Lin et al, Hypertension 1995;26:847-53.
Nicolaas et al, Pharm Res 1996;13:1686-92.
Collins et al. PNAS 2002;99;16899-16903.
Abbey, S. and Potter, L. “Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B”Endocrinology, 2003, 144:240-246.
Angus, R.M. et al. “Effect of inhaled atrial natriuretic peptide on methacholine induced bronchoconstriction in asthma”Clin Exp Allergy1994, 24:784-788.
Angus, R.M. et al. “Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction”Am. J. Respir. Crit. Care Med., 1995, 151:2003-2005.
Bliss, D. et al. “Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines”J Natl Can Inst, 1990, 82:305-310.
Boiteau, R. et al. “Increase in atrial natriuretic factor (ANF) in acute severe asthma (ASA)”Am Rev Res Dis., 1988, 137:A484.
Chanez, P. et al. “Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma”J. Allergy Clin. Immunol., 1990, 86:321-324.
Chen, S. et al. “1,25 dihydroxyvitamin D amplifies type A natriuretic peptide receptor expression and activity in target cells”J. Am. Soc. Nephrol., 2005, 16:329-339.
Delporte, C. et al. “Discovery of a potent atrial natriuretic peptide antagonist for ANPAreceptors in the human neuroblastoma NB-OK-1 cell line”Eur. J. Pharmacol., 1992, 224(2-3):183-188.
Drewett, J.G. and Garbers, D.L. “The family of guanylyl cyclase receptors and their ligands”Endocrine Reviews, 1994, 15(2):135-162.
El-Ayoubi, R. et al. “Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist”Br. J. Pharmacol., 2005, 145:50-56.
Ernst, P. “Review article: the role of inflammation in the pathogenesis of gastric cancer”Aliment Pharmacol Ther., 1999, 13(1):13-18.
Fonarow, G.C. et al. “Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure”Rev. Cardiovasc. Med., 2003, 4(suppl 4):S20-S28.
Fujiseki, Y. et al. “Natriuretic peptide receptors, NPR-A and NPR-B, in cultured rabbit retinal pigment epithelium cells”Jpn. J. Pharmacol., 1999, 79(3):359-368.
Fürst, R. et al. “Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation”Circ. Res., 2005, 96:43-53.
Gower, W.R. et al. “Regulation of atrial natriuretic peptide secretion by cholinergic and PACAP neurons of the gastric antrum”Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 284:G68-G74.
Greenberg, B.D. et al. “Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor”Nature, 1984, 312(5995):656-658.
Greten, F.R. et al. “IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer”Cell, 2004, 118:285-296.
Hamet, P. and Tremblay, J. “Aspects physiologiques et physiopathologiques du facteur natriuretique auriculaire”Nephrologie, 1987, 8:7-12, abstract.
Hulks, G. et al. “Effect of atrial natriuretic factor on bronchomotor tone in the normal human airway”Clin Sci1990;79:51-55.
Hulks, G. and Thomson, N.C. “High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects”Eur. Respir. J., 1994, 7:1593-1597.
Hulks, G. and Thomson, N.C. “Inhaled atrial natriuretic peptide and asthmatic airways”Br. Med J, 1992, 304:1156.
Ishii, Y. et al. “Effects of atrial natriuretic peptide on Type II alveolar epithelial cells of the rat lung. Autoradiographic and morphometric studies”J Anat., 1989, 166:85-95.
Izumi, T. et al. “Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injury”J Clin Invest2001, 108:203-213.
Jin, H. et al. “Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats”J. Clin. Invest., 1996, 98:969-976.
Kanwal, S. et al. “Intracellular fragments of the natriuretic peptide receptor-C (NPR-C) attenuate dopamine efflux”Endocrinology, 1999, 140(3):1118-1124.
Kelly, R. and Struthers, A. “Are natriuretic peptides clinically useful as markers of heart failure?”Ann. Clin. Biochem., 2001, 38:94-102.
Khurana, M.L. and Pandey, K.N. “Receptor-mediated stimulatory effect of atrial natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on testosterone production in purified mouse Leydig cells: Activation of cholesterol side-chain cleavage enzyme”Endocrinology, 1993, 133:2141-2149.
Kiemer, A. and Vollmar, A. “Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide”J Biol Chem, 1998, 273:13444-13451.
Kiemer, A. et al. “cGMP-mediated inhibition of TNF-α production by the atrial natriuretic peptide in murine macrophages”J Immunol, 2000, 165:175-181.
Kumar, R. et al. “Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinse C in vascular smooth muscle cells”Hypertension, 1997, 29(part 2):414-421.
Kumar, M. et al. “Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection”Vaccine199
Li Q. Janice
Saliwanchik Lloyd & Saliwanchik
University of South Florida
LandOfFree
Materials and methods for treatment of allergic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for treatment of allergic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for treatment of allergic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158373